Cetrorelix preserves follicular viability in Cyclophosphamid-induced ovarian toxicity

Anticancer drugs are known to have great impact on spermatogenesis process and germinal epithelium. The present study is to investigate the preventive effect of Cetrorelix (GnRH antagonist) on Cyclophosphamide- induced spermatogenic defect.

Methods and Materials: 

Fifty adult female mice aging 6-8 weeks (30±4 gr) were divided into 3 groups as: Control, Experimental 1 and Experimental 2. The animals in Experimental 1 group received Cyclophosphamide (2.5 mg/kg, ip) for 5 days and in Experimental 2 group received Cetrorelix (0.25 mg/kg, ip) one week before Cyclophosphamide treatment and continued for 3 weeks. The mice in all groups were sacrificed 35 days after the last injection. Ovarian follicles were isolated mechanically and the viability was studied by trypan blue staining.

Ovarian follicles of animals in Experimental 2group, retained higher percentage of normal morphology (P<0.001) than which in Experimental 1 group and their condition were similar to control group.

These results indicate that the Cetrorelix administration before cancer treatment may protect ovarian tissue against side effects of cisplatin.